Mylan NV (NASDAQ:MYL) Shares Acquired by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund lifted its stake in shares of Mylan NV (NASDAQ:MYL) by 9.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 250,662 shares of the company’s stock after buying an additional 22,412 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Mylan were worth $4,773,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in MYL. Pzena Investment Management LLC lifted its stake in Mylan by 0.3% during the first quarter. Pzena Investment Management LLC now owns 21,027,676 shares of the company’s stock worth $595,924,000 after purchasing an additional 71,010 shares during the last quarter. Geode Capital Management LLC lifted its stake in Mylan by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock valued at $215,460,000 after buying an additional 1,026,731 shares during the last quarter. FIL Ltd lifted its stake in Mylan by 14.1% in the first quarter. FIL Ltd now owns 6,468,868 shares of the company’s stock valued at $183,327,000 after buying an additional 799,051 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Mylan by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,120,516 shares of the company’s stock valued at $167,704,000 after buying an additional 538,334 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its stake in Mylan by 15.6% in the first quarter. Clearbridge Investments LLC now owns 4,677,312 shares of the company’s stock valued at $132,555,000 after buying an additional 632,297 shares during the last quarter. 84.03% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have issued reports on MYL shares. Cantor Fitzgerald cut their target price on Mylan from $31.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, June 12th. UBS Group cut their target price on Mylan to $23.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 28th. Mizuho raised their target price on Mylan from $25.00 to $27.00 and gave the company a “neutral” rating in a research note on Tuesday. BidaskClub upgraded Mylan from a “sell” rating to a “hold” rating in a research note on Thursday, June 20th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of Mylan in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $32.07.

NASDAQ:MYL traded down $0.11 during mid-day trading on Thursday, reaching $20.79. 306,688 shares of the stock were exchanged, compared to its average volume of 8,041,378. The business’s fifty day moving average price is $18.69. The company has a market cap of $10.71 billion, a price-to-earnings ratio of 4.53, a PEG ratio of 1.07 and a beta of 1.76. Mylan NV has a 1-year low of $16.63 and a 1-year high of $39.59. The company has a quick ratio of 0.85, a current ratio of 1.37 and a debt-to-equity ratio of 1.06.

Mylan (NASDAQ:MYL) last released its earnings results on Monday, July 29th. The company reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.08. The firm had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.82 billion. Mylan had a return on equity of 18.93% and a net margin of 0.30%. Mylan’s revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.07 earnings per share. As a group, research analysts expect that Mylan NV will post 4.24 earnings per share for the current year.

Mylan Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Read More: Why is the Consumer Price Index (CPI) important?

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.